Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study
Viruses · 2025
DOI: 10.3390/v17070949 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Viruses, 2025. Verfasst von Jae Hyun Yoon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Chonnam National University Hospital and Medical School, Gwangju 61469, Republic of Korea. Hauptthemen laut MEDLINE: Sofosbuvir, Antiviral Agents, Heterocyclic Compounds, 4 or More Rings, Carbamates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chonnam National University Hospital Biomedical Research Institute.
Abstract (Originalsprache)
Background
The advent of direct-acting antivirals (DAAs) has marked a significant milestone in the therapeutic landscape of hepatitis C, greatly improving treatment efficacy. A therapeutic regimen encompassing sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX) has demonstrated strong efficacy across all genotypes of the hepatitis C virus (HCV) and has recently been incorporated into the Korean healthcare system. This study aimed to evaluate the real-world efficacy and safety of these antivirals in the South Korean population.
Methods
This prospective, multicenter, observational study enrolled patients with chronic HCV treated with SOF/VEL-based regimens at six hospitals between November 2022 and January 2024. DAA-naïve patients received SOF/VEL ± ribavirin for 12 weeks. Patients who had failed prior DAA therapy received SOF/VEL/VOX for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks post-treatment (SVR12).
Results
Among 101 patients treated with SOF/VEL, the mean age was 64.71 years, and 40.9% were male. Genotypes 1b and 2 were identified in 40.6% and 59.4% of patients, respectively. Two patients had a history of interferon-based treatment. The mean baseline HCV RNA level was 3,088,097 IU/mL. Cirrhosis was observed in 26.7% of patients (21.8% compensated; 5.0% decompensated). Of the 101 patients, 12 were lost to follow-up. Among the 89 patients who completed follow-up, SVR12 was achieved in 100.0% (89/89), including 5 patients with decompensated cirrhosis. In the SOF/VEL/VOX group, 17 patients were treated. The mean age was 61.84 years, 29.4% were male, and four had compensated cirrhosis. One patient was lost to follow-up. SVR12 was achieved in 100.0% (16/16) of the patients who completed follow-up. No serious adverse events (≥grade 3) were reported in either group during the DAA treatment period.
Conclusions
In this first prospective real-world study in South Korea, SOF/VEL-based regimens demonstrated excellent efficacy and safety, achieving 100% SVR12 in the per-protocol population, including patients with cirrhosis and prior treatment failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Chonnam National University Hospital and Medical School, Gwangju 61469, Republic of Korea.
- Department of Gastroenterology and Hepatology, Jeonbuk National University Hospital and Medical School, Jeonju 54896, Republic of Korea.
- Department of Gastroenterology and Hepatology, Wonkwang University Hospital and Medical School, Iksan 54538, Republic of Korea.
- Department of Gastroenterology and Hepatology, Chosun University Hospital and Medical School, Gwangju 61469, Republic of Korea.
- Department of Gastroenterology and Hepatology, Jeju Halla Hospital, Jeju 63127, Republic of Korea.
- Department of Gastroenterology and Hepatology, Hwasun Chonnam National University Hospital and Medical School, Hwasun 58128, Republic of Korea.
ORCID-Profile: Jae Hyun Yoon, Jin Dong Kim, Ga Ram You
Förderung
- Chonnam National University Hospital Biomedical Research Institute
Zitieren
APA
Yoon, J. H., Lee, C. H., Jo, H. G., Cho, J. Y., Kim, J. D., Kim, J. W., You, G. R., Cho, S. B., & Choi, S. K. (2025). Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study. Viruses. https://doi.org/10.3390/v17070949
Vancouver
Yoon JH, Lee CH, Jo HG, Cho JY, Kim JD, Kim JW, et al. Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study. Viruses. 2025. doi:10.3390/v17070949
BibTeX
@article{Yoon2025,
author = {Yoon, Jae Hyun and Lee, Chang Hun and Jo, Hoon Gil and Cho, Ju-Yeon and Kim, Jin Dong and Kim, Jin Won and You, Ga Ram and Cho, Sung Bum and Choi, Sung Kyu},
title = {Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17070949}
}
EUVIMED